<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601844</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-HV-1982</org_study_id>
    <secondary_id>2020-000300-11</secondary_id>
    <nct_id>NCT04601844</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers</brief_title>
  <official_title>An Open-Label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of Subcutaneously Administered Human Monoclonal Antibody Pozelimab in Combination With Single Doses of Subcutaneously Administered siRNA Cemdisiran in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of ascending&#xD;
      doses of subcutaneous (SC) pozelimab and SC cemdisiran when administered on the same day or&#xD;
      sequentially 28 days apart.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To assess the concentration-time profiles of total pozelimab, total complement component&#xD;
           5 (C5), cemdisiran, and cemdisiran metabolite(s) following single ascending doses of SC&#xD;
           pozelimab and SC cemdisiran when administered on the same day or sequentially 28 days&#xD;
           apart&#xD;
&#xD;
        -  To assess the pharmacodynamic (PD) profile of ascending doses of SC pozelimab and SC&#xD;
           cemdisiran, as well as when administered on the same day or sequentially 28 days apart&#xD;
&#xD;
        -  To assess the immunogenicity of pozelimab and cemdisiran&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Actual">July 23, 2021</completion_date>
  <primary_completion_date type="Actual">July 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of pozelimab in serum over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of cemdisiran in plasma over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total C5 over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total complement hemolytic activity assay (CH50) over time</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibodies (ADA) to pozelimab</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibodies (ADA) to cemdisiran</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cemdisiran at dose 1 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cemdisiran at dose 2 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cemdisiran at dose 2 SC single dose and pozelimab at dose 2 SC single dose, both administered on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pozelimab</intervention_name>
    <description>Single dose administered subcutaneously</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>REGN3918</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemdisiran</intervention_name>
    <description>Single dose administered SC</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>ALN-CC5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Has a body mass index less than 30 kg/m2 at the screening visit&#xD;
&#xD;
          2. Judged to be in good health as defined in the protocol&#xD;
&#xD;
          3. Is in good health based on laboratory safety testing obtained at the screening visit&#xD;
             NOTE: Subject with a history of Gilbert's disease can be enrolled in the study&#xD;
&#xD;
          4. Willing to undergo vaccination against Neisseria meningitidis unless subjects have&#xD;
             documentation of completed series of vaccinations within the past 2 years of the&#xD;
             screening visit&#xD;
&#xD;
          5. Must have two negative COVID-19 tests taken 48 hours apart and within 7 days prior to&#xD;
             study drug administration&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as&#xD;
             assessed by the investigator that may confound the results of the study or poses an&#xD;
             additional risk to the subject by study participation&#xD;
&#xD;
          2. Hospitalization (&gt;24 h) for any reason within 30 days of the screening visit&#xD;
&#xD;
          3. Has a confirmed positive drug test result at the screening visit and/or prior to&#xD;
             enrollment; or a history of recreational drug use (eg, marijuana) and/or drug or&#xD;
             alcohol abuse within a year prior to the screening visit&#xD;
&#xD;
          4. Is positive for HIV, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody&#xD;
             (HBcAb), hepatitis C antibody and positive for qualitative (ie, detected) HCV RNA test&#xD;
             at the screening visit&#xD;
&#xD;
          5. Within the previous 2 months of the screening visit has a history of bacterial,&#xD;
             protozoal, parasitic or viral infection (including COVID-19) and/or persistent chronic&#xD;
             or active recurring infection which requires treatment with antibiotics, antivirals,&#xD;
             or antifungals&#xD;
&#xD;
          6. Known or suspected COVID-19 disease&#xD;
&#xD;
          7. Known allergy or intolerance to penicillin class antibiotics or macrolides&#xD;
&#xD;
        NOTE: Other protocol-defined Inclusion/ Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Antwerp</city>
        <zip>B-2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

